LAMIVUDINE AND ZIDOVUDINE
- Product NDC
- 68180-284
- 11-digit product format
- 681800284
- Labeler code
- 68180
- Product ID
- 68180-284_8abc1453-959b-411d-b18a-1814bcc98192
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- LAMIVUDINE AND ZIDOVUDINE
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Lupin Pharmaceuticals, Inc.
- Application
- ANDA090246
- Marketing category
- ANDA
- Marketing start
- 2012-05-16
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE; ZIDOVUDINE
- Active strength
- 150 mg/1; mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 68180-284-07 | 68180028407 | 60 TABLET in 1 BOTTLE (68180-284-07) | 60 tablet | 2012-05-16 | 0000-00-00 | No | No | Current |